- Although there has been quite a bit of research into the contribution of genes to the risk of MS and the immune cells involved in MS onset, a lot still remains unknown.
- Australian and international researchers have come up with a genetic map of MS, which has more than doubled the gene changes known to play a role in MS.
- These findings have also expanded the knowledge of the immune cells that play a role in MS onset.
What is known about the genetics and immune cells involved in MS risk?
Over the past decade, the genetic architecture of MS has gradually emerged, and over 200 gene variations have been linked to MS. These studies have shed light on the role of the adaptive immune system in MS onset. The adaptive immune system is the part of the immune system that reacts to specific attacks and gains memory after being attacked the first time, meaning that it can react faster to future attacks. But more recent studies, including this new one, suggest that other parts of the immune system may also be involved in MS.
What did the researchers do?
Published in the prestigious journal, Science, Australian and international researchers as part of the International MS Genetics Consortium, looked at 47,429 people with MS and 68,374 people without MS to determine any further genetic changes that play a role in how MS starts and the cells that might be involved.
How many MS risk gene variations did the researchers find?
The researchers found a total of 233 independent gene changes linked to MS risk – 32 of these changes were located in a genetic region called the major histocompatibility complex (MHC), the area of the genome which contains the most significant risk MS genes.
For the first time ever, a MS risk gene variation was discovered on the X chromosome – one of the sex chromosomes – in a region that is specific to T cells, a type of immune cell involved in MS. The remaining 200 MS risk gene variations were located in different regions of the genome.
Which immune cells and tissues are affected by these genetic changes?
The gene changes had an effect on many different types of immune cells. As well as T cells, which have been thoroughly studied in MS, these changes were also found to have an effect on B cells, another type of immune cell which have only been studied in MS more recently.
While cells of the brain, such as neurons and astrocytes were not affected by the genetic changes, microglia, the immune cells of the brain, were affected.
This suggests that the innate immune system, which is the non-specific immune system that comes into play within hours of a new exposure, may also play a role in MS risk.
What do these MS risk genes do?
From the identified MS risk gene changes, the researchers prioritised 551 MS risk genes. This is more than double the previous known genes linked to MS! These MS risk genes were found to be involved in the development and maturation of immune cells such as B cells (part of the adaptive immune system) and natural killer cells (part of the innate immune system).
To get an idea of how these genes may work together to contribute to MS risk, the researchers looked at the interactions of proteins made by these MS risk genes. About one-third of these proteins had some sort of interaction, and there were thirteen smaller groups with stronger interactions – this is much higher than previous studies and will help prioritise proteins for further study in the future.
What is the significance of this work?
This new genetic map of MS has doubled the previous knowledge of MS risk genes. It is exciting that a genetic change was identified on the X chromosome, although it is unlikely that this is the only factor contributing to the higher incidence of MS in women. This is a first step towards understanding the genetic contributions of this strong bias.
These exciting findings also show that a variety of immune cells contribute to MS risk and that both the adaptive and innate arms of the immune system play a role in MS risk. This research sets the stage for further studies to uncover the sequence of events that lead to disease onset and may pave the way for new effective therapies.